Related Experiment Video
Updated: Jul 9, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models
B G Szczepankiewicz1, G Liu, H S Jae
1Pharmaceutical Products Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA. bruce.g.szczepankiewicz@abbott.com
Abstract:
During a screen for compounds that could inhibit cell proliferation, a series of new tubulin-binding compounds was identified with the discovery of oxadiazoline 1 (A-105972). This compound showed good cytotoxic activity against non-multi-drug-resistant and multi-drug-resistant cancer cell lines, but its utility in vivo was limited by a short half-life. Medicinal chemistry efforts led to the discovery of indolyloxazoline 22g (A-259745), which maintained all of the in vitro activity seen with oxadiazoline 1, but also demonstrated a better pharmacokinetic profile, and dose-dependent in vivo activity. Over a 28 day study, indolyloxazoline 22g increased the life span of tumor-implanted mice by up to a factor of 3 upon oral dosing. This compound, and others of its structural class, may prove to be useful in the development of new chemotherapeutic agents to treat human cancers.
Insights
Researchers discovered new tubulin-binding compounds for cancer treatment. Indolyloxazoline 22g shows promising in vitro and in vivo anti-cancer activity, increasing lifespan in mice.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Tubulin-binding compounds are investigated for cancer chemotherapy.
- Oxadiazoline 1 (A-105972) demonstrated cytotoxic activity but had poor pharmacokinetics.
- Development of novel anti-cancer agents with improved properties is crucial.
Purpose of the Study:
- To identify novel tubulin-binding compounds with anti-cancer properties.
- To improve the pharmacokinetic profile and in vivo efficacy of oxadiazoline 1.
- To evaluate the anti-cancer potential of indolyloxazoline 22g.
Main Methods:
- Compound screening for inhibition of cell proliferation.
- In vitro cytotoxicity assays against various cancer cell lines.
- In vivo efficacy studies in tumor-implanted mice with oral dosing.
Main Results:
- Discovery of oxadiazoline 1, a tubulin-binding agent with cytotoxic effects.
- Identification of indolyloxazoline 22g with retained in vitro activity and enhanced pharmacokinetics.
- Indolyloxazoline 22g demonstrated dose-dependent in vivo anti-tumor activity, increasing lifespan up to 3-fold.
Conclusions:
- Indolyloxazoline 22g represents a promising lead compound for cancer chemotherapy.
- This structural class of compounds warrants further investigation for therapeutic applications.
- Improved pharmacokinetic profiles are key for developing effective in vivo anti-cancer agents.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
